Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Glioblastoma 12Brain Neoplasms 6Glioma 3Gliosarcoma 2Carcinoma, Non-Small-Cell Lung 2Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Melanoma 1HER2-positive Metastatic Breast Cancer 1Astrocytoma 1Adenoviridae Infections 1Adenocarcinoma 1

Interventions

3-Iodobenzylguanidine 13lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4Temozolomide 4Specimen Handling 4anlotinib 3Magnetic Resonance Spectroscopy 3Everolimus 3pegfilgrastim 2olaparib 2cabozantinib 2belzutifan 2Radiotherapy 2Phenoxybenzamine 2Nivolumab 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1tipifarnib 1temsirolimus 1talazoparib 1spartalizumab 1pentetreotide 1penpulimab 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × atezolizumab × CNS × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡